Skip to Main Content

Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors (nic_physo)

Conditions

Mental Health & Behavioral Research | Tobacco Addiction

What is the purpose of this trial?

The purpose of the study is to measure the sensitivity of NCFHEB binding to changes in endogenous acetylcholine levels in healthy smoking and nonsmoking subjects, and in schizophrenic smoking and nonsmoking subjects. We hypothesize that physostigmine-induced elevated ACh levels will lead to a reduction in the availability of nicotinic receptors for the binding of the radioligand. We hypothesize there will be greater increase in ACh level (or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects. We hypothesize there will be greater increase in ACh level (or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects with schizophrenia, but the extent of this change will be different than in controls.

  • Trial with
    Yale University School of Medicine
  • Start Date
    08/31/2013
  • End Date
    02/28/2018
Trial Image

For more information about this study, contact:

Jon Mikael Anderson

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/22/2018
  • Study HIC
    #1210010989